SINGAPORE – A new Covid-19 remedy may be available in Singapore and beyond until early 2021, as local biotechnology company Hummingbird Bioscience joins the big names to take steps to control coronavirus.
The experimental antibody therapy, which works by “building a wall” around inflamed cells, aims to supply the must-have remedy even as pharmaceutical giants advance vaccine development, the company’s co-founder told CNBC. Tuesday.
“The key to combating this pandemic is to build an arsenal of options, whether preventive, such as vaccines, and remediesArray. . . as antibody therapies,” Jerome Boyd-Kirkup said.
Treatment, called Hummingbird 115, will offer a “real option” within the arsenal, either to treat patients before a vaccine is found, or to treat those who do not respond well once it is available, he said.
The news comes when hopes of receiving a coronavirus vaccine were cheered on Monday, when US-based Moderna was in the middle of the world. He said his experimental vaccine was 94. 5% effective at preventing Covid-19. declared that their vaccine was more than 90% effective.
Small-scale human testing of Hummingbird 115 began in Singapore last month after the company obtained approval from fitness authorities. These tests are expected to pass to larger Phase 3 tests in Singapore and beyond until December, as the company aims to implement the remedy in the New Year.
“Our goal is to achieve accessibility of this treatment for patients in early 2021,” Boyd-Kirkup said.
However, he added that it was “a bit early to speculate” on the pricing models.
Launched in Singapore in 2015, Hummingbird Bioscience gained $65 million of investors, adding SK Holdings and Mirae Asset Capital in South Korea to its sites in Asia, Europe and the United States. agreement and which, on the other hand, was being implemented with foreign partners and regulators to provide solutions “where they are needed. “
Do you have any confidential information? Us to listen to you.
Sign up for loose newsletters and get more CNBC in your inbox
Get it in your inbox and more information about our services.
© 2020 CNBC LLC All rights are reserved. An NBCUniversal department
Knowledge is a real-time snapshot: data is delayed for at least 15 minutes, monetary and global industry news, inventory quotes, and market knowledge and analysis.
Data also by